Free Trial
Earnings Season Is Here. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion
OTCMKTS:MKGAF

Merck KGaA (MKGAF) Stock Price, News & Analysis

Merck KGaA logo
$167.21 +9.24 (+5.85%)
As of 10/20/2026 03:55 PM Eastern

About Merck KGaA Stock (OTCMKTS:MKGAF)

Advanced

Key Stats

Today's Range
$167.14
▼
$169.04
50-Day Range
$149.97
▼
$168.41
52-Week Range
$116.68
▼
$175.56
Volume
350 shs
Average Volume
640 shs
Market Capitalization
$21.61 billion
P/E Ratio
25.53
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Merck KGaA is a German science and technology company headquartered in Darmstadt, Germany. Founded in 1668, it is one of the world’s oldest operating pharmaceutical and chemical companies. The company operates under the name EMD Serono in the United States and Canada, where the Merck name is associated with a separate company.

Merck KGaA operates through three primary business sectors: Healthcare, Life Science and Electronics. Its Healthcare business develops and markets prescription medicines, including treatments in oncology, neurology and immunology, as well as fertility and other specialty-care products. The Life Science business supplies laboratory products, equipment, services and technologies used in pharmaceutical manufacturing, biotechnology, research and academic laboratories.

The Electronics business develops materials and solutions for the semiconductor and display industries, including specialty chemicals, semiconductor materials and liquid-crystal technologies. Merck KGaA serves customers in markets around the world through research, manufacturing and commercial operations across multiple regions. Belén Garijo has served as the company’s chief executive officer and chair of its executive board since 2021.

AI Generated. May Contain Errors.

Merck KGaA Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
29th Percentile Overall Score

MKGAF MarketRank™: 
1.43593519882 of 5 stars

Merck KGaA scored higher than 29% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Merck KGaA.

  • Earnings Growth

    Earnings for Merck KGaA are expected to grow by 8.21% in the coming year, from $9.75 to $10.55 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Merck KGaA is 25.53, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 40.77.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Merck KGaA is 25.53, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 195.56.

  • Price to Book Value per Share Ratio

    Merck KGaA has a P/B Ratio of 0.79. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Merck KGaA's valuation and earnings.
  • Percentage of Shares Shorted

    0.70% of the float of Merck KGaA has been sold short.
  • Short Interest Ratio / Days to Cover

    Merck KGaA has a short interest ratio ("days to cover") of 473.73, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Merck KGaA has recently increased by 7.11%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Merck KGaA does not currently pay a dividend.

  • Dividend Growth

    Merck KGaA does not have a long track record of dividend growth.

  • News Sentiment

    Merck KGaA has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Merck KGaA this week, compared to 0 articles on an average week.
Receive MKGAF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merck KGaA and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MKGAF Stock News Headlines

ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.tc pixel
Merck KGaA (OTCMKTS:MKGAF) Shares Gap Down - Time to Sell?
See More Headlines

MKGAF Stock Analysis - Frequently Asked Questions

Merck KGaA's stock was trading at $147.60 at the beginning of 2026. Since then, MKGAF stock has increased by 13.3% and is now trading at $167.21.

Shares of MKGAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
10/20/2026
Next Earnings (Estimated)
11/12/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:MKGAF
CIK
N/A
Employees
62,461
Year Founded
1891

Profitability

EPS (Trailing Twelve Months)
$6.81
Trailing P/E Ratio
25.53
Forward P/E Ratio
17.15
P/E Growth
N/A
Net Income
$3.06 billion
Net Margins
12.60%
Pretax Margin
15.64%
Return on Equity
10.17%
Return on Assets
5.74%

Debt

Debt-to-Equity Ratio
0.27
Current Ratio
1.31
Quick Ratio
0.84

Sales & Book Value

Annual Sales
$22.72 billion
Price / Sales
0.95
Cash Flow
$50.36 per share
Price / Cash Flow
3.32
Book Value
$212.00 per share
Price / Book
0.79

Miscellaneous

Outstanding Shares
129,240,000
Free Float
N/A
Market Cap
$21.61 billion
Optionable
Not Optionable
Beta
0.96

Social Links

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

This page (OTCMKTS:MKGAF) was last updated on 10/20/2026 by MarketBeat.com Staff.
From Our Partners